Agendia Responds to IQWiG Assessment for Reimbursement of Gene Expression-based Breast Cancer Recurrence Tests
IRVINE, CA and AMSTERDAM, 5 December 2016 โ Agendia, Inc., Read More
Agendiaโs MammaPrint and BluePrint Tests Highlighted in Multiple Presentations at the 2016 San Antonio Breast Cancer Symposium, Adding Further Clinical Utility
Agendia will also host two additional educational opportunities for physicians Read More
Agendiaโs proven breast cancer recurrence assay, MammaPrint, now available in the Middle East
Agendia signs partnership agreement with Cryogene and Mist for Middle Read More
Agendia Announces the Award of a New Category 1 CPT Code from the American Medical Association for the MammaPrint 70-Gene Breast Cancer Recurrence Assay
The company also announces new patient awareness platform to help Read More
Agendia Expands its Business Activities in Germany
The โBRIDGEโ initiative offers German patients free access to Agendiaโs Read More
Agendia appoints three leading cancer physicians to its Medical Advisory Board
IRVINE, CA and AMSTERDAM โ 12 October 2016 โ Agendia, Read More
Agendia Responds to “Clinical Insights on MINDACT”
ย Dear Dr. Febbo, I recently received an email from Read More
New England Journal of Medicine Publishes MINDACT Trial Results Proving the Clinical Utility of MammaPrint in Assisting Physicians to Identify Early-Stage Breast Cancer Patients who can Safely Forgo Chemotherapy
46% of patients identified as high risk for recurrence according Read More
New Data Shows Agendiaโs MammaPrint can Prevent Under and Over Treatment of Breast Cancer Patients with an Intermediate/Indeterminate OncotypeDx Recurrence Score
The PRospective study Of MammaPrint in breast cancer patients with Read More
Agendia Appoints Dr. Gabriel Hortobagyi as Chairman to their Medical Advisory Board
Company also announces new ASCO data presentation from the prospective Read More
